Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)

The US Food and Drug Administration issued a black box warning related to the risk of reactivation of overt/occult hepatitis B virus (HBV) infection during direct acting-antivirals (DAA) treatment. This review evaluated the prevalence of HBV reactivation after hepatitis C virus (HCV) pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisaturo, Mariantonietta, Macera, Margherita, Alessio, Loredana, Calò, Federica, Coppola, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784257/
https://www.ncbi.nlm.nih.gov/pubmed/31540223
http://dx.doi.org/10.3390/v11090850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784257/
https://www.ncbi.nlm.nih.gov/pubmed/31540223
http://dx.doi.org/10.3390/v11090850

Ejemplares similares